The Effect of the Prosthetic Group on the Pharmacologic Properties of 18 F-labeled Rhodamine B, a Potential Myocardial Perfusion Agent for PET

We recently reported the development of the 2-[ 18 F]fluoroethyl ester of rhodamine B as a potential positron emission tomography (PET) tracer for myocardial perfusion imaging. This compound, which was prepared using a [ 18 F]fluoroethyl prosthetic group, has significant uptake in the myocardium in rats, but also demonstrates relatively high liver uptake and is rapidly hydrolyzed in vivo in mice. We have now prepared 18 F-labeled rhodamine B using three additional prosthetic groups (propyl, diethylene glycol, and triethylene glycol) and found that the prosthetic group has a significant effect on the in vitro and in vivo properties of these compounds. Of the esters prepared to date, the diethylene glycol ester is superior in terms of in vitro stability and pharmacokinetics. These observations suggest that the prosthetic group plays a significant role in determining the pharmacological properties of 18 F-labeled compounds. They also support the value of continued investigation of 18 F-labeled rhodamines as PET radiopharmaceuticals for myocardial perfusion imaging.

[1]  D. Dey,et al.  Automatic 3D registration of dynamic stress and rest (82)Rb and flurpiridaz F 18 myocardial perfusion PET data for patient motion detection and correction. , 2011, Medical physics.

[2]  M. Phelps,et al.  Phase I, First-in-Human Study of BMS747158, a Novel 18F-Labeled Tracer for Myocardial Perfusion PET: Dosimetry, Biodistribution, Safety, and Imaging Characteristics After a Single Injection at Rest , 2011, The Journal of Nuclear Medicine.

[3]  S. Nekolla,et al.  The next generation of cardiac positron emission tomography imaging agents: discovery of flurpiridaz F-18 for detection of coronary disease. , 2011, Seminars in nuclear medicine.

[4]  A. Fischman,et al.  Evaluation of (4-[18F]Fluorophenyl)triphenylphosphonium Ion. A Potential Myocardial Blood Flow Agent for PET , 2011, Molecular Imaging and Biology.

[5]  S. Nekolla,et al.  Simplified Quantification of Myocardial Flow Reserve with flurpiridaz F 18: Validation with Microspheres in a Pig Model , 2011, The Journal of Nuclear Medicine.

[6]  D. Berman,et al.  Development of a method for the determination of dose ratio and minimum inter-injection interval for a one-day rest-stress protocol with BMS747158 PET myocardial perfusion agent , 2010 .

[7]  S. Treves,et al.  Biodistribution and stability studies of [18F]fluoroethylrhodamine B, a potential PET myocardial perfusion agent. , 2010, Nuclear medicine and biology.

[8]  S. Robinson,et al.  Cardiac imaging and safety evaluation of BMS747158, a novel PET myocardial perfusion imaging agent, in chronic myocardial compromised rabbits , 2010, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.

[9]  Xianzhong Zhang,et al.  Preparation and biodistribution of [18F]FP2OP as myocardial perfusion imaging agent for positron emission tomography. , 2010, Bioorganic & medicinal chemistry.

[10]  B. Långström,et al.  Synthesis and in vitro evaluation of 18F-labelled di- and tri(ethylene glycol) metomidate esters , 2009 .

[11]  G. Beller,et al.  A welcomed new myocardial perfusion imaging agent for positron emission tomography. , 2009, Circulation.

[12]  B. Långström,et al.  (18)F-labelled metomidate analogues as adrenocortical imaging agents. , 2009, Nuclear medicine and biology.

[13]  X. Shao,et al.  Fluorine‐18 Radiopharmaceuticals , 2009 .

[14]  Lisheng Cai,et al.  Chemistry with [18F]Fluoride Ion , 2008 .

[15]  F. Bengel,et al.  Cardiovascular nuclear imaging: from perfusion to molecular function , 2008, Heart.

[16]  S. Robinson,et al.  Synthesis and biological evaluation of pyridazinone analogues as potential cardiac positron emission tomography tracers. , 2008, Journal of medicinal chemistry.

[17]  S. Nekolla,et al.  Initial Characterization of an 18F-Labeled Myocardial Perfusion Tracer , 2008, Journal of Nuclear Medicine.

[18]  Mary Guaraldi,et al.  BMS-747 158-02: A novel PET myocardial perfusion imaging agent , 2007, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.

[19]  S. Robinson,et al.  Mechanism of uptake and retention of F-18 BMS-747 158-02 in cardiomyocytes: a novel PET myocardial imaging agent , 2007, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.

[20]  L. Becker,et al.  Assessment of Severity of Coronary Artery Stenosis in a Canine Model Using the PET Agent 18F-Fluorobenzyl Triphenyl Phosphonium: Comparison with 99mTc-Tetrofosmin , 2007, Journal of Nuclear Medicine.

[21]  Daniel S. Berman,et al.  Myocardial perfusion and function: Single photon emission computed tomography , 2006, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.

[22]  R. Dannals,et al.  Characterization of uptake of the new PET imaging compound 18F-fluorobenzyl triphenyl phosphonium in dog myocardium. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[23]  E. Novellino,et al.  Syntheses, biological evaluation, and molecular modeling of 18F-labeled 4-anilidopiperidines as mu-opioid receptor imaging agents. , 2005, Journal of medicinal chemistry.

[24]  B. Abraham,et al.  Photophysical, Photochemical, and Tumor-selectivity Properties of Bromine Derivatives of Rhodamine-123 , 2005, Photochemistry and photobiology.

[25]  Y. Zea‐Ponce,et al.  Synthesis and in vitro evaluation of new benzovesamicol analogues as potential imaging probes for the vesicular acetylcholine transporter. , 2005, Bioorganic & medicinal chemistry.

[26]  R. Huesman,et al.  Kinetic analysis of 18F-fluorodihydrorotenone as a deposited myocardial flow tracer: comparison to 201Tl. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[27]  R. Dannals,et al.  Radiosynthesis of 3-[18F]fluoropropyl and 4-[ 18F]fluorobenzyl triarylphosphonium ions , 2004 .

[28]  M. Komiyama,et al.  Predominant role of basicity of leaving group in α-effect for nucleophilic ester cleavage , 2004 .

[29]  Paiboon Reungpatthanaphong,et al.  Rhodamine B as a mitochondrial probe for measurement and monitoring of mitochondrial membrane potential in drug-sensitive and -resistant cells. , 2003, Journal of biochemical and biophysical methods.

[30]  A. Studenov,et al.  Synthesis and properties of 18F-labeled potential myocardial blood flow tracers. , 2001, Nuclear medicine and biology.

[31]  M. Nascimento,et al.  Ab Initio Calculations of Absolute pKa Values in Aqueous Solution II. Aliphatic Alcohols, Thiols, and Halogenated Carboxylic Acids , 2000 .

[32]  M. Goodman,et al.  Synthesis and evaluation of a new fluorine-18 labeled rotenoid as a potential PET probe of mitochondrial complex I activity , 1999 .

[33]  F. Speleman,et al.  Technetium-99m sestamibi imaging in paediatric neuroblastoma and ganglioneuroma and its relation to P-glycoprotein , 1999, European Journal of Nuclear Medicine.

[34]  Alun G. Jones,et al.  Interspecies variation in biodistribution of technetium (2-carbomethoxy-2-isocyanopropane)6+. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[35]  M. Dhalla,et al.  In vivo studies of unlabeled and radioiodinated rhodamine-123. , 1992, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.

[36]  B. Holman,et al.  Comparison of neutral and cationic myocardial perfusion agents: characteristics of accumulation in cultured cells. , 1992, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.

[37]  I. L. Arbeloa,et al.  Dimeric states of rhodamine B , 1982 .

[38]  F. Fahey,et al.  Synthesis of fluorine-18 labeled rhodamine B: A potential PET myocardial perfusion imaging agent. , 2010, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[39]  A. Składanowski,et al.  Induction of the multixenobiotic/multidrug resistance system in various cell lines in response to perfluorinated carboxylic acids. , 2008, Acta biochimica Polonica.

[40]  S. Robinson,et al.  Assessment of 18F-labeled mitochondrial complex I inhibitors as PET myocardial perfusion imaging agents in rats, rabbits, and primates , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[41]  H. Coenen.  Fluorine-18 labeling methods: Features and possibilities of basic reactions. , 2007, Ernst Schering Research Foundation workshop.

[42]  Josef Machac,et al.  Cardiac positron emission tomography imaging. , 2005, Seminars in nuclear medicine.

[43]  C. Crouzel,et al.  Chemistry of β +-Emitting Compounds Based on Fluorine-18 , 2002 .

[44]  N. Savaraj,et al.  Rho(0) tumor cells: a model for studying whether mitochondria are targets for rhodamine 123, doxorubicin, and other drugs. , 2000, Biochemical pharmacology.

[45]  B. Sobel,et al.  Cardiac Positron Emission Tomography , 1996, Developments in Cardiovascular Medicine.

[46]  W. L. Mock,et al.  Concerning the relative acidities of simple alcohols , 1990 .

[47]  T. Lampidis,et al.  Selective killing of carcinoma cells "in vitro" by lipophilic-cationic compounds: a cellular basis. , 1985, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.